Evaluation of in-vitro dissolution and in-vivo absorption for two different film-coated pellets of clarithromycin

Archives of Pharmacal Research

Volumn 28, Issue 8, 2005, Pages 977-982

  Zhang, Xiang Rong ^a   Chen, Xiao Yan ^a   Hu, Lian Dong ^a   Tang, Xing ^a   Li, San Ming ^a   Zhong, Da Fang ^a  

^a SHENYANG PHARMACEUTICAL UNIVERSITY   (China)

Author keywords

Clarithromycin; Film coated pellets; In vitro; In vivo

Indexed keywords

EID: 30644463917     PISSN: 02536269     EISSN: 02536269     Source Type: Journal    
DOI: 10.1007/BF02973886     Document Type: Article

References (15)

1. Amidon, G. L., Lennemas, H., Shah, V. P., and Crison, J. R., A theoretical basis for a biopharmaceutical drug classification: the correlation of in vitro drug product dissolution and in vivo bioavailability. Pharm. Res., 12, 413-420 (1995).
2. Amighi, K., Timmermans, J., Puigadevall, J., Baltes, E., and Moës, A. J., Peroral sustained-release film-coated pellets as a means to overcome physicochemical and biological drugrelated problems. I. In vitro development and eveluation. Drug Dev. Ind. Pharm., 24, 509-515 (1998).
3. Arimori, K., Miyamoto, S., Fukuda, K., Nakamura, C., and Nakano, M., Characteristic difference in gastrointestinal excretion of clarithromycin and roxithromycin. Biopharm. Drug Dispos., 19, 433-438 (1998).
4. Bodmeier, R., Tableting of coated pellets. Eur. J. Pharm. Biopharm., 43, 1-8 (1997).
5. Chu, S. Y., Deaton, R., and Cavanaugh, J., Absolute bioavailability of clarithromycin after oral administration in humans. Antimicrob. Agents Chemother., 36, 1147-1150 (1992a).
6. Chu, S. Y., Granneman, G. R., Pichotta, P. J., Decout, J. P., Girault, J., and Fourtilan, J. B., Effect of moderate or severe hepatic impairment on clarithromycin pharmacokinetics. J. Clin. Pharmacol., 33, 480-485 (1993).
7. Chu, S. Y., Park, Y., Locke, C., Wilson, D. S., and Cavanaugh, J. C., Drug-food interaction potential of clarithromycin, a new macrolide antimicrobial. J. Clin. Pharmacol., 32, 32-36 (1992b).
8. Dressman, J. B., Berardi, R. R., Dermentzoglou, L. C., Russell T. L., Schmaltz, S. P., Barnett, J. L., and Jarvenpaa, K. M., Upper gastrointestinal (GI) pH in young, healthy men and women. Pharm. Res., 7, 756-761 (1990).
9. Erah, P. O., Barrett, D. A., and Shaw, P. N. Ion-pair highperformance liquid chromatographic assay method for the assessment of clarithromycin stability in aqueous solution and in gastric juice. J. Chromatogr. B., 682, 73-78 (1996).
10. Grubel, P. and Cave, D. R., Factors affecting solubility and penetration of clarithromycin through gastric mucus. Alim. Pharmacol. Ther., 12, 569-576 (1998).
11. Guay, D. R., Gustavson, L. E., Devcich, K. J., Zhang, J., Cao, G., and Olson, C. A., Pharmacokinetics and tolerabilty of extended-release clarithromycin. Clin. Ther., 23, 566-577 (2001).
12. Nakagawa, Y., Itai, S., Yoshida, T., and Nagai, T., Physicochemical properties and stability in the acidic solution of a new macrolide antibiotic, clarithromycin, in comparision with erythromycin. Chem. Pharm. Bull., 40, 725-728 (1992).
13. Rodvold, K. A., Clinical pharmacokinetics of clatrithromycin. Clin. Pharmacokinet., 37, 385-398 (1999).
14. Sathe, P. M., Tsong Y., and Shah V. P., In-vitro dissolution profile comparision: statistics and analysis, model dependent approch. Pharm. Res., 13, 1799-1803 (1996).
15. Sousa, J. J., Sousa, A., Moura, M. J., Podczeck, F., and Newton, J. M., The influence of core materials and film coating on the drug release from coated pellets. Int. J. Pharm., 233, 111-122 (2002).